Phone hold times were short, and the agent answered quickly when we called
The minor peaks observed at m/z values higher than 359.3 may be due to the formation of adducts between dityrosine and the other fragments present in the ionization chamber
McEwen BS, Bowles NP, Gray JD, Hill MN, Hunter RG, Karatsoreos IN, et al
The powder should dissolve into a clear, colorless solution
The expected timeline: Phase 3 trials completing: Results rolling out throughout the rest of this year FDA submission: Expected sometime after full Phase 3 data is available Potential FDA approval: Estimated for late 2027 at the earliest Commercial availability: If approved, launch would follow in 2027-2028 For those tracking retatrutide availability updates , the situation is evolving